Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
NCT ID: NCT02177786
Last Updated: 2019-11-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
334 participants
INTERVENTIONAL
2014-06-30
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
NCT02509624
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
NCT00501462
A Study in Participants With Diabetic Kidney Disease
NCT01113801
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
NCT02312050
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
NCT01030679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Selonsertib 2 mg
Participants will receive selonsertib 2 mg for 48 weeks.
Selonsertib
Tablets administered orally once daily
Selonsertib 6 mg
Participants will receive selonsertib 6 mg for 48 weeks.
Selonsertib
Tablets administered orally once daily
Selonsertib 18 mg
Participants will receive selonsertib 18 mg for 48 weeks.
Selonsertib
Tablets administered orally once daily
Placebo to match selonsertib
Participants will receive placebo to match selonsertib for 48 weeks.
Placebo to match selonsertib
Tablets administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Selonsertib
Tablets administered orally once daily
Placebo to match selonsertib
Tablets administered orally once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetes mellitus diagnosis for at least 6 months
* eGFR (MDRD) at screening ≥ 15 mL/min/1.73m\^2 to \< 60 mL/min/1.73m\^2
* Urine albumin to creatinine ratio (UACR) as follows:
* Stage/Stratum 3a: eGFR range 45 to \< 60 mL/min; UACR ≥ 600 mg/g
* Stage/Stratum 3b: eGFR range 30 to \< 45 mL/min; UACR ≥ 300 mg/g
* Stage/Stratum 4: eGFR range 15 to \< 30 mL/min; UACR ≥ 150 mg/g
* Receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARB) at a minimum dose deemed appropriate for the individual by the investigator and be at a stable dose for the last three months
* Individuals not on ACEi/ARB may be screened if there is documented intolerance to ACE inhibitor and/or ARB
Exclusion Criteria
* HbA1c \> 9.5%
* Non-diabetic kidney disease
* UACR \> 5000 mg/g on any measurement during screening
* End stage renal disease (ESRD; receiving peritoneal dialysis, hemodialysis, or status post renal transplantation) or anticipated to occur within the treatment period
* Unstable cardiovascular disease
* Pregnant or lactating females
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States
Chase Medcare
Huntsville, Alabama, United States
Choice Medicine
Toney, Alabama, United States
Akdhc Medical Research Services, Llc
Peoria, Arizona, United States
Akdhc Medical Research Services, Llc
Phoenix, Arizona, United States
Akdhc Medical Research Services, Llc
Phoenix, Arizona, United States
Akdhc Medical Research Services, Llc
Prescott, Arizona, United States
Robert J. Bloomberg, MD
Tempe, Arizona, United States
AKDHC East Office
Tucson, Arizona, United States
Clinical Research Connections, LLC
Harrisburg, Arkansas, United States
North America Research Institute
Azusa, California, United States
California Institute of Renal Research
Chula Vista, California, United States
California Institute of Renal Research Inc.
El Centro, California, United States
Renal Consultants Medical Group Granada Hills
Granada Hills, California, United States
Torrance Clinical Research
Lomita, California, United States
IMD Medical Group
Los Angeles, California, United States
Academic Medical Research Institute
Los Angeles, California, United States
Kidney Research Center
Lynwood, California, United States
Apex Research of Riverside
Riverside, California, United States
San Francisco General Hospital
San Francisco, California, United States
Clearview Medical Research, LLC
Santa Clarita, California, United States
American Institute of Research
Whittier, California, United States
Omega Research Consultants
DeBary, Florida, United States
Creekside Medical Research
DeLand, Florida, United States
Riverside Clinical Research
Edgewater, Florida, United States
ASA Clinical Research
Jupiter, Florida, United States
FPA Clinical Research
Kissimmee, Florida, United States
The Chappel Group LLC
Kissimmee, Florida, United States
South Florida Research Institute
Lauderdale Lakes, Florida, United States
Prestige Clinical Research Center Inc
Miami, Florida, United States
International Physicians Research / Nephrology Associates of South Miami
Miami, Florida, United States
Tellus Clinical Research, Inc
Miami, Florida, United States
Coral Research Clinic Corp
Miami, Florida, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States
Discovery Medical Research Group
Ocala, Florida, United States
Central Florida Internists
Orlando, Florida, United States
Sunset Point Medical Associates DBA
Palm Harbor, Florida, United States
Pines Clinical Research Inc.
Pembroke Pines, Florida, United States
Central Florida Internists
Saint Cloud, Florida, United States
Florida Pulmonary Research Institute
Winter Park, Florida, United States
Rockdale Medical Research Associates
Conyers, Georgia, United States
John H. Stroger Jr. Hospital Of Cook County
Chicago, Illinois, United States
Midwest Endocrinology
Crystal Lake, Illinois, United States
Beacon Medical Group Kidney and Hypertension Center
Mishawaka, Indiana, United States
West Broadway Clinic
Council Bluffs, Iowa, United States
Hutchinson Clinic, P.A
Hutchinson, Kansas, United States
Kansas Nephrology Research Institute, LLC
Wichita, Kansas, United States
L-MARC Research Center
Louisville, Kentucky, United States
Four Rivers Clinical Research
Paducah, Kentucky, United States
Research Nurse Specialists, LLc
Lafayette, Louisiana, United States
Crescent City Clinical Research Center
Metairie, Louisiana, United States
Tulane University
New Orleans, Louisiana, United States
Internal Medicine Specialists
New Orleans, Louisiana, United States
Green Clinic LLC
Ruston, Louisiana, United States
Northwest Louisiana Nephrology
Shreveport, Louisiana, United States
Southern Clinical Research
Zachary, Louisiana, United States
Johns Hopkins Hospital/University
Baltimore, Maryland, United States
A. Kaldun Nossuli MD Research
Bethesda, Maryland, United States
Wayne State University
Detroit, Michigan, United States
Apex Medical Research.Com
Flint, Michigan, United States
Elite Clinical Research
Flint, Michigan, United States
Troy Internal Medicine, PC
Troy, Michigan, United States
VA Medical Center
Kansas City, Missouri, United States
Mercury Street Medical Group, PLLC, Big Sky Clinical Research, LLC
Butte, Montana, United States
Alegent Creighton Health
Omaha, Nebraska, United States
Creighton Diabetes Center
Omaha, Nebraska, United States
Nephrology and Hypertension Associates of New Jersey
Voorhees Township, New Jersey, United States
Albuquerque Clinical Trials
Albuquerque, New Mexico, United States
Nephrology Associates, PC
Flushing, New York, United States
Mountain Kidney and Hypertension Associates
Asheville, North Carolina, United States
Boice-Willis Clinic
Rocky Mount, North Carolina, United States
Carolina Research Center
Shelby, North Carolina, United States
Hightop Medical Research Center
Cincinnati, Ohio, United States
Craig S Thompson MD LLC
Marion, Ohio, United States
Your Diabetes Endocrine Nutrition Group Inc
Mentor, Ohio, United States
Chris Sholer, MD, PC
Oklahoma City, Oklahoma, United States
Bend Memorial Clinic
Bend, Oregon, United States
Southeast Renal Research Institute
Chattanooga, Tennessee, United States
Knoxville Kidney Center
Knoxville, Tennessee, United States
Arlington Nephrology
Arlington, Texas, United States
MW Clinical Research Center
Beaumont, Texas, United States
Padre Coast Clinical Research
Corpus Christi, Texas, United States
Corsicana Medical Research, PLLC
Corsicana, Texas, United States
Texas Tech Univ. Health Sciences Center
El Paso, Texas, United States
TVC Clinical Research
Gonzales, Texas, United States
Diagnostic Clinic of Houston
Houston, Texas, United States
Mercury Clinical Research
Houston, Texas, United States
Lakewood Family Practice
Houston, Texas, United States
Southwest Clinical Trials
Houston, Texas, United States
Southwest Houston Research, Ltd.
Houston, Texas, United States
HMRI CCAT Pearland
Pearland, Texas, United States
Clinical Advancement Center, PLLC
San Antonio, Texas, United States
Briggs Clinical Research, LLC
San Antonio, Texas, United States
San Antonio Kidney Disease Center Physicians Group, P.L.L.C.
San Antonio, Texas, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Val R. Hansen, M.D.
Bountiful, Utah, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
University of Virginia
Charlottesville, Virginia, United States
University of Wisconsin
Madison, Wisconsin, United States
Zablocki VAMC
Milwaukee, Wisconsin, United States
BC Diabetes
Vancouver, British Columbia, Canada
Co-Medica Research Network
Courtice, Ontario, Canada
Clinical Research Solutions, Inc.
Kitchener, Ontario, Canada
OTT Healthcare Inc.
Scarborough Village, Ontario, Canada
Toronto East General Medical Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD; GS-US-223-1015 Investigators. Effects of Selonsertib in Patients with Diabetic Kidney Disease. J Am Soc Nephrol. 2019 Oct;30(10):1980-1990. doi: 10.1681/ASN.2018121231. Epub 2019 Sep 10.
Tesch GH, Ma FY, Han Y, Liles JT, Breckenridge DG, Nikolic-Paterson DJ. ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice. Diabetes. 2015 Nov;64(11):3903-13. doi: 10.2337/db15-0384. Epub 2015 Jul 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS-US-223-1015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.